Zofenopril Protects Against Myocardial Ischemia–Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability

BACKGROUND: Zofenopril, a sulfhydrylated angiotensin‐converting enzyme inhibitor (ACEI), reduces mortality and morbidity in infarcted patients to a greater extent than do other ACEIs. Zofenopril is a unique ACEI that has been shown to increase hydrogen sulfide (H(2)S) bioavailability and nitric oxid...

Descripción completa

Detalles Bibliográficos
Autores principales: Donnarumma, Erminia, Ali, Murtuza J., Rushing, Amanda M., Scarborough, Amy L., Bradley, Jessica M., Organ, Chelsea L., Islam, Kazi N., Polhemus, David J., Evangelista, Stefano, Cirino, Giuseppe, Jenkins, J. Stephen, Patel, Rajan A. G., Lefer, David J., Goodchild, Traci T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015391/
https://www.ncbi.nlm.nih.gov/pubmed/27381758
http://dx.doi.org/10.1161/JAHA.116.003531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015391/
https://www.ncbi.nlm.nih.gov/pubmed/27381758
http://dx.doi.org/10.1161/JAHA.116.003531

Ejemplares similares